Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Aveo

This page shows the latest Aveo news and features for those working in and with pharma, biotech and healthcare.

Aveo’s tivozanib is knocked back by FDA once again

Aveo’s tivozanib is knocked back by FDA once again

Try as it might, Aveo Oncology just can’t persuade the FDA to accept a new regulatory filing for its kidney cancer candidate tivozanib. ... analysis at 263 events, and that the median OS for tivozanib is worse than that of sorafenib", notes Aveo.

Latest news

More from news
Approximately 5 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2016 Deal Watch March 2016

    Collaboration – marketing &distribution. $171. AVEO Oncology/ CANbridge Life Sciences. AV-203; ErbB3 (HER3) inhibitory antibody for oesophageal cancer.

  • Deal Watch December 2015 Deal Watch December 2015

    405. Aveo (US). EUSA. Collaboration, licence. Pre-registration tivozanib for renal cell carcinoma.

  • Pharma deals in August 2015 Pharma deals in August 2015

    Another early stage deal [opportunities do not seem to hang around long!] was that between Novartis and Aveo where Novartis paid an upfront fee of $15m to secure rights to AV ... Collaboration extension. 330. Aveo. Novartis. AV 380 antibody for

  • Deal Watch table for November 2014 Deal Watch table for November 2014

    Acquisition of voucher. 125. AVEO Oncology / Ophthotech Corporation. VEGF tyrosine kinase inhibitor tivozanib.

  • Pharma deals during February 2014 Pharma deals during February 2014

    In another termination of an oncology deal, Astellas exercised its right to terminate its collaboration with Aveo Oncology to develop the tyrosine kinase inhibitor, tivozanib, for “strategic reasons”.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

  • AVEO appoints Nikhil Mehta as its senior VP, regulatory and quality assurance AVEO appoints Nikhil Mehta as its senior VP, regulatory and quality assurance

    He joins the biopharma from Tang Capital Management. AVEO Oncology has appointed Dr Nikhil Mehta as senior vice president or regulatory and quality assurance, a role that will see him oversee ... I anticipate Dr Mehta’s integration into the AVEO team

  • AVEO's financial head joins ImmunoGen AVEO's financial head joins ImmunoGen

    David Johnston appointed chief financial officer. David Johnston has left his role as chief financial officer of AVEO Pharmaceuticals to join ImmunoGen in the same role. ... Johnston's switch comes after more than six years at AVEO having joined the

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES COLLECTIVE

Hello. We are the Total Health creative agency. It’s our collective mix of talent that gets us to truly different...

Latest intelligence

Rare diseases: not so rare after all
The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...

Quick links